Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
EQ
Equillium, Inc.
Equillium's pipeline focuses on immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$76.16M |
$1.20
-6.64%
|
|
AMWL
American Well Corporation
Amwell uses Carepoint and related hardware as part of its care-delivery ecosystem, aligning with medical devices/biometrics.
|
$76.08M |
$4.72
-0.84%
|
|
VATE
INNOVATE Corp.
MediBeacon and R2 Technologies manufacture medical devices/biometrics (skin therapy devices and transdermal kidney function monitoring).
|
$74.68M |
$5.62
+2.55%
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$74.65M |
$1.30
+3.17%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$73.97M |
$1.63
+3.16%
|
|
ASRT
Assertio Holdings, Inc.
ROLVEDON and related oncology-supportive care products position Assertio in Biotech - Oncology as its growth drivers.
|
$73.66M |
$11.47
+3.05%
|
|
TENX
Tenax Therapeutics, Inc.
TNX-103 levosimendan is a cardiovascular drug candidate in Phase 3 for PH-HFpEF, making Cardiovascular Drugs the direct product category.
|
$73.23M |
$16.07
+1.10%
|
|
NNBR
NN, Inc.
Precision medical device components manufacturing, including implant-related parts (Medical Device Components).
|
$72.93M |
$1.45
-0.68%
|
|
SRTS
Sensus Healthcare, Inc.
Sensus manufactures medical devices and biometric sensing technologies, including SRT therapy systems and related imaging components.
|
$72.17M |
$4.42
+0.68%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$72.13M |
$7.22
|
|
LUNG
Pulmonx Corporation
Zephyr Endobronchial Valve and related medical devices are core product offerings.
|
$72.12M |
$1.77
-3.01%
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$71.97M |
$5.69
-1.90%
|
|
BEAT
HeartBeam, Inc.
Direct diagnostic equipment derived from HeartBeam's synthesized 12-lead ECG device.
|
$71.37M |
$2.08
-5.68%
|
|
GOCO
GoHealth, Inc.
GoHealth's core offering is health insurance enrollment and management for Medicare plans.
|
$71.24M |
$2.50
+4.17%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
|
$69.56M |
$4.68
-1.68%
|
|
ATYR
aTyr Pharma, Inc.
Efzofitimod is a biologic immunomodulator addressing inflammation in ILD, aligning with Immunology Therapeutics.
|
$69.43M |
$0.71
+0.03%
|
|
BYSI
BeyondSpring Inc.
BeyondSpring develops oncology therapeutics (Plinabulin) with a novel SIMBA mechanism, directly addressing cancer and CIN.
|
$68.97M |
$1.76
-0.56%
|
|
EUDA
EUDA Health Holdings Limited
EUDA's core biotech activity is a stem cell platform and cell therapy development using iPSCs.
|
$68.73M |
$1.88
+2.46%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$68.58M |
$7.32
-3.81%
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$68.07M |
$0.69
+0.07%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$67.75M |
$1.02
+2.00%
|
|
CRVO
CervoMed Inc.
Neflamapimod is an orally administered, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$67.36M |
$7.30
+3.18%
|
|
PMVP
PMV Pharmaceuticals, Inc.
PMVP is a biotech company focused on oncology, developing rezatapopt to restore p53 function in TP53-mutant cancers, representing its core product category.
|
$66.77M |
$1.25
-0.40%
|
|
COEP
Coeptis Therapeutics, Inc.
GEAR Cell Therapy Platform is a core cell therapy biotech asset.
|
$66.45M |
$13.18
-3.48%
|
|
ANL
Adlai Nortye Ltd.
The company’s pipeline includes oral small-molecule therapeutics (e.g., AN4005, AN9025), aligning with the Oral Small Molecule Therapeutics category.
|
$66.35M |
$1.66
-1.19%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell off-the-shelf T cell therapies and the TVGN 489 program position Tevogen as a cell therapy biotech focused on oncology and infectious disease.
|
$66.11M |
$0.34
+2.73%
|
|
MGX
Metagenomi, Inc. Common Stock
MGX's core platform is gene therapy/gene editing tools enabling therapeutic gene modification, including in vivo MGX-1.00 programs.
|
$65.31M |
$1.78
+2.30%
|
|
SOTK
Sono-Tek Corporation
Medical device coatings are a key application (balloon catheters, stents), linking Sono-Tek to Medical Devices & Equipment.
|
$64.56M |
$3.96
-6.26%
|
|
TISI
Team, Inc.
Laboratory Testing & Advisory Services aligns with Team's lab testing and inspection capabilities within its IHT segment.
|
$64.51M |
$14.64
-0.91%
|
Showing page 27 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
